IN SILICO ANALYSIS OF STRUCTURAL REQUIREMENTS FOR THIOPHENE DERIVATIVES AGAINST POLO LIKE KINASE-1 (PLK1)

Abstract

Objective: Development of anti-mitotic drugs for chemotherapy of cancer has been one of the main focuses of research in 21st century. Present work aims to study the structural requirements of thiophene derivatives against PLK1 as a target for designing novel strategies for cancer chemoprevention. To understand the structural requirements that will lead to enhanced inhibitory potencies, we have carried out 3D-QSAR (quantitative structure-activity relationship) studies on a series of thiophene derivatives as PLK1 receptor inhibitors.Methods: CoMFA, CoMSIA and molecular docking studies were performed on a series of thiophene derivatives as PLK1 receptor inhibitors using Sybyl 6.7.Results: We have successfully derived statistically significant model from 100 thiophene derivatives and validated, it against an external test set of 34 compounds and 66 molecules used in the training set. The CoMFA model yielded q2-0.845, r2-0.978. While the CoMSIA model yielded q2-0.804, r2-0.968. The predictive ability of these models supported by docking studies; produced better docking scores and binding affinity to the specified target polo like kinase1 (3THB) and moreover, the 3D QSAR model used for suggesting the next-generation lead analogues.Conclusion: 3D-QSAR has been established for a series of Polo like Kinase1 (PLK1) inhibitors employing the most widely used techniques CoMFA and CoMSIA. The conclusions derived from both models are similar and reliable. Docking studies are also performed to obtain the bioactive confirmations for the whole data-set. The obtained 3D contour maps along with the docking results provided a rational clue for the design of more favorable anti-mitotic agents. Overall, the structural modifications of the lead molecule have achieved to improve selective PLK1 inhibitory activity. 

Authors and Affiliations

Shravan Kumar Gunda, Vijaya Lakshmi Lokirevu, Shyamasundara Chary Rudroju, Sri Swathi Mutya, Mahmood Shaik

Keywords

Related Articles

LARVICIDAL ACTIVITY OF ESSENTIAL OILS OF THYMUS VULGARIS AND ORIGANUM MAJORANA (LAMIACEAE) AGAINST OF THE MALARIA VECTOR ANOPHELES LABRANCHIAE (DIPTERA: CULICIDAE)

Objective: We evaluated the properties of larvicidal activity of essential oils of Thymus vulgaris and Origanum majorana family of Lamiaceae collected at Taounate province in the North East of Morocco, against the larvae...

PHYTOCHEMICAL SCREENING AND HPTLC FINGERPRINTING ANALYSIS OF ETHANOLIC EXTRACT OF ERYTHRINA VARIEGATA L. FLOWERS

Objective: Medicinal plants possess phytochemicals that accumulate in various parts of plant like leaves, flowers, vegetables and roots that exert defense mechanism and protect us from various diseases. The present study...

EFFECTS OF CO-TRIMOXAZOLE CO-ADMINISTRATION ON THE PHARMACOKINETICS OF AMODIAQUINE IN HEALTHY VOLUNTEERS

Objectives: Amodiaquine (AQ) is a 4-aminoquinoline antimalarial drug that is rapidly and extensively metabolized mainly by CYP2C8 enzyme to N-desethylamodiaquine (DEAQ). Co-trimoxazole (CTZ) is a combination (sulfamethox...

A STUDY ON ANTIOXIDANT AND ANTI-AGING PROPERTIES OF FEW MEDICINAL PLANTS

Objective: The present study was undertaken to appraise the antioxidant and antiaging properties of some important medicinal plants like Syzygium cumini L. (Jamun, the Indian Blackberry), Tinospora cordifolia L. (Giloy)...

DIFFERENCE SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS ESTIMATION OF MOXIFLOXACIN AND CEFIXIME TRIHYDRATE IN BULK AND COMBINED DOSAGE FORM

Objective: To develop rapid, accurate, reproducible, validated and economical difference spectroscopy method for the simultaneous determination of moxifloxacin (MFN) and cefixime (CEF) in tablet dosage forms.Methods: The...

Download PDF file
  • EP ID EP578689
  • DOI -
  • Views 62
  • Downloads 0

How To Cite

Shravan Kumar Gunda, Vijaya Lakshmi Lokirevu, Shyamasundara Chary Rudroju, Sri Swathi Mutya, Mahmood Shaik (2015). IN SILICO ANALYSIS OF STRUCTURAL REQUIREMENTS FOR THIOPHENE DERIVATIVES AGAINST POLO LIKE KINASE-1 (PLK1). International Journal of Pharmacy and Pharmaceutical Sciences, 7(6), 203-213. https://europub.co.uk./articles/-A-578689